Latest Paradigm Biocapital Advisors LP Stock Portfolio
$4.89Billion– No. of Holdings #35
Paradigm Biocapital Advisors LP Performance:
2026 Q1: 11.48%YTD: 11.48%2025: 33.45%
Performance for 2026 Q1 is 11.48%, and YTD is 11.48%, and 2025 is 33.45%.
About Paradigm Biocapital Advisors LP and 13F Hedge Fund Stock Holdings
On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Paradigm Biocapital Advisors LP reported an equity portfolio of $4.9 Billions as of 31 Mar, 2026.
The top stock holdings of Paradigm Biocapital Advisors LP are ACLX, RVMD, NUVL. The fund has invested 13.6% of it's portfolio in ARCELLX INC and 13.2% of portfolio in REVOLUTION MEDICINES INC .
The fund managers got completely rid off CIDARA THERAPEUTICS INC (CDTX), CRINETICS PHARMACEUTICALS IN (CRNX) and BRIDGEBIO PHARMA INC (BBIO) stocks. They significantly reduced their stock positions in UROGEN PHARMA LTD (URGN), BRIDGEBIO ONCOLOGY THERAPEUT and SCHOLAR ROCK HLDG CORP (SRRK). Paradigm Biocapital Advisors LP opened new stock positions in INSMED INC (INSM), BELITE BIO INC (BLTE) and CENTESSA PHARMACEUTICALS PLC (CNTA). The fund showed a lot of confidence in some stocks as they added substantially to TERNS PHARMACEUTICALS INC (TERN), VIRIDIAN THERAPEUTICS INC (VRDN) and ORUKA THERAPEUTICS INC.
The top stock holdings of Paradigm Biocapital Advisors LP are ACLX, RVMD, NUVL. The fund has invested 13.6% of it's portfolio in ARCELLX INC and 13.2% of portfolio in REVOLUTION MEDICINES INC .
The fund managers got completely rid off CIDARA THERAPEUTICS INC (CDTX), CRINETICS PHARMACEUTICALS IN (CRNX) and BRIDGEBIO PHARMA INC (BBIO) stocks. They significantly reduced their stock positions in UROGEN PHARMA LTD (URGN), BRIDGEBIO ONCOLOGY THERAPEUT and SCHOLAR ROCK HLDG CORP (SRRK). Paradigm Biocapital Advisors LP opened new stock positions in INSMED INC (INSM), BELITE BIO INC (BLTE) and CENTESSA PHARMACEUTICALS PLC (CNTA). The fund showed a lot of confidence in some stocks as they added substantially to TERNS PHARMACEUTICALS INC (TERN), VIRIDIAN THERAPEUTICS INC (VRDN) and ORUKA THERAPEUTICS INC.
Paradigm Biocapital Advisors LP Equity Portfolio Value
Last Reported on: 15 May, 2026
Paradigm Biocapital Advisors LP Annual Return Estimates Vs S&P 500
Our best estimate is that Paradigm Biocapital Advisors LP made a return of 11.48% in the last quarter. In trailing 12 months, it's portfolio return was 75.06%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| insmed inc | 205,134,000 |
| belite bio inc | 177,741,000 |
| centessa pharmaceuticals plc | 141,961,000 |
| cytokinetics inc | 97,603,300 |
| tango therapeutics inc | 83,882,500 |
| maze therapeutics inc | 81,920,300 |
| tyra biosciences inc | 78,706,200 |
| mirum pharmaceuticals inc | 57,737,500 |
New stocks bought by Paradigm Biocapital Advisors LP
Additions
| Ticker | % Inc. |
|---|---|
| terns pharmaceuticals inc | 173 |
| viridian therapeutics inc | 118 |
| oruka therapeutics inc | 35.67 |
| spyre therapeutics inc | 33.4 |
| lexeo therapeutics inc | 29.83 |
| apogee therapeutics inc | 20.03 |
| vaxcyte inc | 17.82 |
| genmab a/s | 13.18 |
Additions to existing portfolio by Paradigm Biocapital Advisors LP
Reductions
| Ticker | % Reduced |
|---|---|
| urogen pharma ltd | -61.91 |
| bridgebio oncology therapeut | -61.61 |
| scholar rock hldg corp | -59.96 |
| abivax sa | -45.5 |
| oric pharmaceuticals inc | -29.15 |
| erasca inc | -26.6 |
| eyepoint inc | -14.87 |
Paradigm Biocapital Advisors LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| ocular therapeutix inc | -35,634,300 |
| crinetics pharmaceuticals in | -102,912,000 |
| cidara therapeutics inc | -167,780,000 |
| bridgebio pharma inc | -52,340,300 |
Paradigm Biocapital Advisors LP got rid off the above stocks
Sector Distribution
Paradigm Biocapital Advisors LP has about 81.3% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 81.3 |
| Others | 18.7 |
Market Cap. Distribution
Paradigm Biocapital Advisors LP has about 17.4% of it's portfolio invested in the large-cap and mega-cap stocks.
- MID-CAP
- UNALLOCATED
- LARGE-CAP
- SMALL-CAP
| Category | % |
|---|---|
| MID-CAP | 55.2 |
| UNALLOCATED | 18.7 |
| LARGE-CAP | 17.4 |
| SMALL-CAP | 8 |
Stocks belong to which Index?
About 76% of the stocks held by Paradigm Biocapital Advisors LP either belong to S&P 500 or RUSSELL 2000 index.
- RUSSELL 2000
- Others
| Index | % |
|---|---|
| RUSSELL 2000 | 76 |
| Others | 24 |
Paradigm Biocapital Advisors LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Paradigm Biocapital Advisors LP
Paradigm Biocapital Advisors LP has 35 stocks in it's portfolio. About 67.6% of the portfolio is in top 10 stocks. OLMA proved to be the most loss making stock for the portfolio. ACLX was the most profitable stock for Paradigm Biocapital Advisors LP last quarter.
Last Reported on: 15 May, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx inc | 13.55 | 5,774,020 | 662,973,000 | added | 0.87 | ||
| AGLE | spyre therapeutics inc | 2.02 | 1,957,270 | 98,724,500 | added | 33.4 | ||
| ASMB | assembly biosciences inc | 0.38 | 665,251 | 18,460,700 | unchanged | 0.00 | ||
| BBIO | bridgebio pharma inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BLTE | belite bio inc | 3.63 | 1,114,780 | 177,741,000 | new | |||
| CDTX | cidara therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CNTA | centessa pharmaceuticals plc | 2.90 | 3,574,050 | 141,961,000 | new | |||
| CRNX | crinetics pharmaceuticals in | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CYTK | cytokinetics inc | 1.99 | 1,480,860 | 97,603,300 | new | |||
| ERAS | erasca inc | 3.44 | 10,392,700 | 168,154,000 | reduced | -26.6 | ||
| EWTX | edgewise therapeutics inc | 4.74 | 7,365,040 | 231,999,000 | added | 12.59 | ||
| EYPT | eyepoint inc | 0.83 | 3,142,440 | 40,506,000 | reduced | -14.87 | ||
| GMAB | genmab a/s | 4.37 | 7,967,840 | 213,777,000 | added | 13.18 | ||
| INSM | insmed inc | 4.19 | 1,254,490 | 205,134,000 | new | |||
| IVA | inventiva sa | 0.45 | 4,000,000 | 22,200,000 | unchanged | 0.00 | ||
| MIRM | mirum pharmaceuticals inc | 1.18 | 625,000 | 57,737,500 | new | |||
| NUVL | nuvalent inc | 11.14 | 5,324,430 | 545,488,000 | added | 1.04 | ||
| OCUL | ocular therapeutix inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| OLMA | olema pharmaceuticals inc | 2.44 | 8,020,580 | 119,587,000 | added | 6.31 | ||
| ORIC | oric pharmaceuticals inc | 0.44 | 1,701,220 | 21,554,400 | reduced | -29.15 | ||